Dr. Lindsay Rosenwald – Know More About Lindsay Rosenwald

Dr. Lindsay Rosenwald plays an important role in the advancement of the biotechnology industry through his strong knowledge of medicine, finance and investing. Dr. Rosenwald’s investment portfolio includes a diversified mixture of promising new drugs and numerous drug research centers.

As a highly esteemed Wall Street venture capitalist, Dr. Lindsay Rosenwald possesses a brilliant reputation that spans almost two decades. His expertise in life-sciences research in various fields is well known among his peers. Dr. Rosenwald leads the way in the areas of innovative R&D within the biotechnology and healthcare industries. Dr. Rosenwald enjoys a unique ability to discover prospective investment opportunities and his contributions in these areas have expanded the vistas of healthcare investing. His achievements in these fields are monumental.

Over the course of his career, Dr. Lindsay A. Rosenwald has created and re-capitalized numerous private and public companies within the biotechnology sector, as well as the life-sciences field.

Dr. Lindsay A. Rosenwald earned his degree in finance at the Pennsylvania State University. Attending the Temple University School of Medicine, he received his MD, later completing his internship at Abington Medical Hospital located in Abington, Pennsylvania.

From 1994 to 2007, Dr. Lindsay A. Rosenwald served as the executive director of Aries Real Estate Fund, which has invested over $1 billion in promising healthcare businesses. As head of the Orion Fund from 2002 to 2006, Dr. Rosenwald invested in biotechnology, focusing on private investments in public equity.

Today, Dr. Rosenwald serves as a director of the Republican Jewish Coalition; he is president of Paramount Group as well, a company, which specializes in investment banking. The Paramount Group also invests in equity management, and research and development, focusing mostly on the biotechnology industry as well as the life-sciences industry.

A recent undertaking for Dr. Lindsay A. Rosenwald, OpusPoint Partners, LLC was founded in 2009 with the purpose of creating and promoting cutting-edge technologies and supporting new achievements in this very specialized industry.

Among the greatest accomplishments of Dr. Lindsay Rosenwald and his staff are the funding of companies like Cougar Biotechnology Inc. Cougar Biotechnology is working on a number of promising cancer treatment drugs. One drug in particular, Abiraterone, treats the most aggressive strains of prostate cancer and shows great promise for future development.

Dr. Rosenwald is president of the Rosenwald Foundation, a non-profit organization based in New York that supports various healthcare, scientific, and educational establishments.

The future of medicine and healthcare is on the verge of a breakthrough that will mean a better world for mankind. OpusPoint Partners intends to be at the front of this push for improved healthcare and medicine by placing solid investments into recent innovations in the field. The face of life science and healthcare will never be the same.

Founded in 2009 by Michael S. Weiss and Dr. Lindsay Rosenwald, OpusPoint Partners is only one of a group of biotech companies created by these two men. Both Weiss and Rosenwald are zealous adherents to the biotechnology world. The two of them together have over 40 years in experience with life science and biotech investing.

Dr. Lindsay Rosenwald is also the founder of another company named Cougar Biotechnology Inc., a Los Angeles-based company which does research on experimental cancer drugs. Researchers and investors have been following Cougar’s progress as the company turns out some exciting products with great potential. A drug in Cougar’s portfolio may have an impact on prostate cancer late-stage treatment. Johnson & Johnson purchased Cougar Biotech Labs on July 10, 2009 for around one billion dollars.

Lindsay Rosenwald and OpusPoint Partners are particularly interested in building sturdy business alliances with the investment and biotechnology communities. Conducting honest investment and open disclosure policies maintains integrity in the relationships and is also forms an organization’s culture of ethics. These practices create strong relationships when observed by all business and industry partners.

OpusPoint Partners and Lindsay Rosenwald are making alliances with several people, research groups, investors and corporations in an attempt to make large strides in medical innovations that will improve disease treatment. They will also help start-up companies to acquire their goals. With the strength of these relationships, Dr. Lindsay Rosenwald and OpusPoint Partners intend to find, and invest in, the most promising research companies on the verge of very big discoveries.

Dr. Lindsay Rosenwald and OpusPoint Partners are taking biotech investment in a new direction. They are encouraging biotech facilities to enforce a morally-sound set of ideals and really sound business practices, in essence to raise the standards of biotech investing. With these ethics, companies can continue to gain high revenues with low associated risks. The company’s own successes using these same set of values serves as a shining example.

Dr. Rosenwald has been involved with these processes for many years. He has been a biotechnology entrepreneur on Wall Street for over 17 years. He has also been actively engaged with founding and recapitalizing a number of public and private biotech and life sciences companies. He has earned a B.S. in Finance and an M.D. from Pennsylvania State University and the Temple University School of Medicine respectively.

His experience also extends to managing billion-dollar funds for healthcare and biotech investment. The Aries Funds has invested over $1 billion in healthcare under his management while the Orion Fund is completely devoted to private biotech investments, mainly PIPEs.

The basis of OpusPoint’s foundation is to create and sustain a vast network of life science and healthcare groups that uphold standards of integrity and honesty in their work. This mold is something quite rare today where companies often engage in unethical practices for the purpose of gaining more profit.

OpusPoint Partners will be a different kind of company. It will be a company firmly committed to maintaining fairness and ethics in business dealings as well as in the actual testing, manufacture and investigation of drugs.

Following the guidance of Michael Weiss and Dr. Lindsay Rosenwald, OpusPoint Partners has a bright path ahead. With a leadership built upon so much experience and expertise, it is not hard to see that the company will play a key role in the groundbreaking changes to come in medicine and healthcare.

Trying to change what have been the accepted standards in medicine for years will take costly time and energy. It will take money and a very keen dedication to ethics to resist the temptation of choices that may promise higher profit but that have little moral value.

Dr. Rosenwald, though, thinks that it can be done. He uses the company as an example – it has already exceeded its goals by helping to finance over 20 companies in less than two years. It is certain that with the use of the right practices and procedures, there will be very high returns in the worlds of drug research and finance.

Dr. Lindsay Rosenwald is part of the Republican Jewish Coalition Board of Directors. He has also made close alliances to leaders of the biotechnology financing sector. OpusPoint Partners will enjoy a prosperous future with Dr. Rosenwald as its leader.

OpusPoint Partners envisions a better world for mankind. A more viable, stronger and healthier world is achievable with improved delivery of healthcare and medicine. OpusPoint Partners will take the baton in making innovative strides in life science and healthcare. They will make a mark by putting strong investments into pioneering methods that lifts the current banner of healthcare.

Dr. Lindsay Rosenwald and Michael S. Weiss established OpusPoint Partners in 2009. Passionate about biotechnology, the two men have founded several biotech companies together over the years. Rosenwald and Weiss carry more than 40 years of experience under their belts in the fields of life science and biotech investing.

Cougar Biotechnology Inc. is yet another company established by Dr. Lindsay Rosenwald. The company, located in Los Angeles, has established a good portfolio conducting research for new cancer drugs. This has gained the company some attention from researchers and investors. One drug can possibly treat late prostate cancer and on July 10, 2009, Cougar Biotech Labs was sold to Johnson & Johnson for close to one billion dollars.

OpusPoint Partners and Lindsay Rosenwald are devoted to establishing viable partnerships with the biotechnology and investment communities. Keeping integrity amongst relations is one key way of doing this, by remaining open and making honest investments. Leaders of the industry and companies must all recognize the importance of this practice to the strength of their relationships.

Lindsay Rosenwald and OpusPoint Partners are coming together with several researchers, investors and corporations that can join together in providing the world with breakthrough treatments to disease. While lending support to emerging companies and their goals, Dr. Lindsay Rosenwald and OpusPoint Partners will join forces in finding the best research companies on the brink of developing medical innovations.

Dr. Lindsay Rosenwald and OpusPoint Partners aim to challenge the current confines of investing in biotechnology. They are aiming for higher goals in investing and are challenging biotech companies to apply better ethical standards to business and production. OpusPoint Partners is an example of how it is possible to gain attractive rewards without high risks by employing well-rounded practices.

Dr. Rosenwald has had plenty of experience with these ideas. He has been on Wall Street for more than 17 years as a biotechnology entrepreneur. He has also been a key person in the development and recapitalization of several public and private biotech and life sciences companies. He holds a B.S. degree in Finance from Pennsylvania State University and obtained his M.D. from the Temple University School of Medicine.

He also has expertise in financial management of large investment funds. He managed billions of dollars in The Aries Funds (1994 to 2007) and the Orion Fund (2002 to 2006). In the first case, funds have been used to invest in healthcare; in the second case investment has been directed totally to biotechnology, specifically PIPEs.

The founding goal of OpusPoint Partners is to establish a sturdy alliance of partnerships in healthcare and life science that have the same ideals of ethical practice. In the current market, it may be hard to find business leaders who will maintain ethical integrity in their aims for positive clinical outcomes and higher profit.

This is one area where OpusPoint Partners will make a difference. The company has proven its commitments to its shareholders and has also shown its dedication to uphold high principles in drug testing, manufacturing and investigating.

Under the leadership of Michael Weiss and Dr. Lindsay Rosenwald, OpusPoint Partners has a successful future ahead. The combined expertise and experience of both men will help to guide the company in selecting innovative options in healthcare and medicine.

But changing age-old practice in medicine and healthcare will take time, money and great commitment. Trying to keep the ethical standard at a high level will require very strong dedication.

Dr. Rosenwald has no doubts this can be done. OpusPoint Partners, for example, has made very strong strides forward in a short period of time. In less than two years, they were able to financially assist more than 20 companies, proving that using better approaches can certainly yield rewards in the area of drug research and financing.

Dr. Lindsay Rosenwald is a member of the Board of Directors of the Republican Jewish Coalition. In addition, he has close relationships with the biotechnology financing sector. OpusPoint Partners will have a successful development under his direction.